
Opinion|Videos|November 26, 2024
Beyond Hot Flashes: The Importance of Sleep in Menopause Management
Key Takeaways
- Sleep disturbances in menopause are independent symptoms, impacting mood, cardiovascular health, and Alzheimer's risk.
- Elinzanetant may improve sleep quality in menopausal women, addressing a critical aspect of menopause management.
Panelists discuss the importance of addressing sleep disturbances in menopause management, even in the absence of vasomotor symptoms (VMS), and explore how emerging research on elinzanetant could impact sleep quality and its links to mood disorders, cardiovascular disease, and Alzheimer disease, while also contemplating the potential shift in the treatment paradigm for VMS with the introduction of new neurokinin-targeted therapies as either standard of care or in combination with other treatments.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- (PINKERTON) Sleep has been identified as an independent symptom from hot flashes. With the emerging research regarding the use of elinzanetant to combat sleep disturbances associated with menopause [such as anticipated data from the NIRVANA trial], how important is it to address sleep as part of menopause management, even in the absence of vasomotor symptoms, and how is sleep quality linked to other complications such as mood disorders, cardiovascular disease, and Alzheimer disease?
- What role do you anticipate elinzanetant to have in this space?
- (FIFFICK) How do you anticipate the treatment paradigm of VMS associated with menopause to shift with the advent of these new neurokinin-targeted therapies?
- Please discuss your thoughts on whether they’ll become a new standard of care, and if you anticipate them being used as monotherapy vs combination therapy.
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
GLP-1 Therapies in 2026: Beyond Blood Sugar and the Scale
2
What ADA 2026 Data Reveal About the Growing Gap in Ketone Monitoring: Eden Miller, DO
3
ACA Enrollment Erosion Deepens After Open Enrollment Ends
4
Efgartigimod Effective in Broad Subsets of Patients With gMG
5
